1. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
- Author
-
Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, and Socinski MA
- Subjects
- Administration, Intravenous, Adult, Aged, Cell Cycle Proteins adverse effects, Cell Cycle Proteins therapeutic use, Disease-Free Survival, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Protein Serine-Threonine Kinases adverse effects, Protein Serine-Threonine Kinases therapeutic use, Proto-Oncogene Proteins adverse effects, Proto-Oncogene Proteins therapeutic use, Pteridines adverse effects, Pteridines pharmacology, Recurrence, Small Cell Lung Carcinoma pathology, Smoking epidemiology, Treatment Failure, Treatment Outcome, Polo-Like Kinase 1, Cell Cycle Proteins antagonists & inhibitors, Lung Neoplasms drug therapy, Protein Serine-Threonine Kinases antagonists & inhibitors, Proto-Oncogene Proteins antagonists & inhibitors, Pteridines administration & dosage, Small Cell Lung Carcinoma drug therapy
- Abstract
Objectives: This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed small cell lung cancer (SCLC). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response, and safety., Materials and Methods: Patients were treated with the recommended phase II dose of 200mg of BI 2536 intravenously every 21days. This was a two-stage design with an early stopping rule in place if responses were not seen in at least 2 of the first 18 enrolled patients., Results and Conclusion: Twenty-three patients were enrolled in the study and 21 patients were evaluable for response. No responses were observed and all 23 patients have progressed. The median PFS was 1.4 months. Treatment was generally well tolerated and the most frequent adverse events were neutropenia, fatigue, nausea, vomiting, and constipation. BI 2536 is not effective in the treatment of sensitive relapsed SCLC. The criteria for expanding the trial to the second stage were not achieved, and the study was terminated for a lack of efficacy., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF